Navigation Links
Circassia Acquires North American and Japanese Rights to Dopexamine

Circassia Establishes Commercial-Scale Supply Chain

Circassia to Develop Dopexamine as Part of Proprietary Post-Surgery

Recovery Protocols

OXFORD, England, October 8 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, announced today that it has acquired the US, Canadian and Japanese development and commercialization rights to dopexamine from the international speciality pharmaceutical company Ipsen. Circassia has also entered into agreements with pharmaceutical manufacturers Excella and Hospira to establish a commercial-scale supply chain for the product.

Circassia is developing dopexamine in a new indication as an integral part of proprietary structured protocols designed to dramatically improve patient recovery following a range of high-risk surgeries. This novel approach, named ToleroCare(R), which Circassia has recently patented, combines the use of dopexamine with the administration of intra-venous fluids to improve tissue oxygenation levels during the recovery period after surgery. The precise use of fluids and dopexamine is based on carefully defined parameters such as heart stroke volume and oxygen delivery index.

ToleroCare therapy has already achieved clinical proof-of-concept in a phase II single-blind, randomized, controlled trial in 122 high-risk general surgery patients in the UK. The study showed that significantly fewer patients who received ToleroCare experienced complications in the 30 day period following surgery compared with those on standard treatment (44% vs. 68%; p = 0.003). In addition, ToleroCare patients recovered significantly quicker, staying in hospital for 17.5 days on average compared with 29.5 days (p = 0.001) for those who received standard therapy.

Dopexamine is a beta2 adrenoceptor and dopamine receptor agonist, which is approved in Europe in indications related to heart failure. Dopexamine is not approved for use currently in the US, Canada or Japan.

"ToleroCare has great potential to dramatically improve patients' recovery following major surgery, as well as to significantly reduce costs by shortening the time spent in hospital. With approximately 825,000 high-risk surgical procedures carried out each year in the US, and the high cost associated with hospital stays, ToleroCare is targeting a major market opportunity," said Steve Harris, Circassia's CEO. "Dopexamine provides Circassia with a further phase II clinical-stage development programme that fits well with our outsourced business model. By establishing a commercial-scale supply chain for dopexamine, we are well positioned to rapidly progress ToleroCare to market."

About Circassia

Circassia is a specialty biopharmaceutical company focused on the fields of allergy and critical care. The company has a highly experienced management team with a proven track record in product development and commercialization, and having successfully completed two fundraising rounds is backed by a syndicate of world-class venture capital and institutional investors, which includes Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune(R). The company is also developing its ToleroTrans(R) organ anti-rejection technology, which uses a similar approach to down-regulate immune responses in transplant patients. Circassia has a number of ongoing development programmes, with the most advanced against cat-dander allergy in phase II clinical testing.
For more information please visit


Steve Harris Rob Budge

CEO RJB Communications

Circassia Tel: +44(0)1865-760969

Tel: +44(0)1865-784574 Mobile: +44(0)7710-741241

SOURCE Circassia Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding
2. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
3. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
4. Neogen Acquires Kane Enterprises
5. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
6. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
7. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
8. NSF International Acquires David Begg Associates
9. United BioSource Acquires Caro Research, Leader in Simulation Modeling
10. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
11. Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services
Post Your Comments:
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a range ... place between the two entities said Poloz. Speaking ... Ottawa , he pointed to the country,s inflation ... federal government. "In ... "Both institutions have common economic goals, why not sit down ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
Breaking Biology Technology:
(Date:5/12/2016)... , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):